RECCE® 327 (R327) demonstrated significant bactericidal activity against ‘superbug’ Acinetobacter baumannii (A. baumannii) demonstrating 99.99999% log reduction (>7.5 log reduction) in adult human...
Results demonstrate efficacy on bacterial growth in participants injected with RECCE® 327 (R327) at the highest tested dose of 4,000mgNo serious adverse events and clinically significant changes...
Positions RECCE® 327 (R327) gel as a potential broad topical therapeutic for all bacterial skin infectionsHuman Research Ethics Committee approval received for Phase II trial of R327 for acute...
SYDNEY, June 20, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced its primary...
SYDNEY, June 12, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd. (ASX:RCE, FSE:R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced it completed...
First participants (male/female) dosed at 4,000mg over 20 minutes, with remaining subjects to be dosed in the near future - 4,000mg highest dosage to date in this clinical trialRECCE® 327 (R327)...
RECCE® 327 (R327) demonstrated >99% log reduction (>2.5 log reduction) in Mycobacterium abscessus lung infections using a nebulizer delivery methodR327 is being evaluated for potential use to...
Recce Pharmaceuticals Ltd, a company developing new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens, announced the China National Intellectual Property Administration has formally granted to Recce Pharmaceuticals a new family of two patents, “Copolymer and Method for Treatment of Bacterial Infection,” for its anti-infectives, with expiry in 2035.
SYDNEY, Australia, May 08, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd. (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced the China...
Independent Safety Committee approves increase of RECCE® 327 (R327) dose to 4,000mg intravenously (IV) over 30 minutes for six subjects, with dosing to start in near weeksR327 dosed at 3,000mg has...